GE Healthcare introduced earlier this year in certain countries and regions, the SenoBright Contrast Enhanced Spectral Mammography (CESM) technology, to help detect and diagnose breast cancer rapidly and accurately, even in the densest part of the breast tissue.
It uses X-rays at multiple energies to create two separate exposures. These resulting images specifically illuminate and highlight areas where there is angiogenesis, growth of small blood vessels potentially related to the presence of cancer.
Watch Dr. Clarisse Dromain, Gustave Roussy Cancer Institute, France, as she shares insights about this innovative imaging technology to aid in breast cancer diagnosis.
The SenoBright option cannot be put into service in countries that require the CE mark until it has been made to comply with CE marking. It may not be available in all regions. SenoBright Contrast Enhanced Spectral Mammography (CESM) is 510(k) pending at the FDA. Not available for sale in the United States.